- Home
- MVST vs SWKH Comparison
MVST vs SWKH Comparison
Compare MVST & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- SWKH
- Stock Information
- Founded
- MVST 2006
- SWKH 1996
- Country
- MVST United States
- SWKH United States
- Employees
- MVST N/A
- SWKH N/A
- Industry
- MVST Industrial Machinery/Components
- SWKH Diversified Financial Services
- Sector
- MVST Miscellaneous
- SWKH Finance
- Exchange
- MVST Nasdaq
- SWKH Nasdaq
- Market Cap
- MVST 182.8M
- SWKH 201.5M
- IPO Year
- MVST N/A
- SWKH 1999
- Fundamental
- Price
- MVST $2.39
- SWKH $16.04
- Analyst Decision
- MVST Buy
- SWKH
- Analyst Count
- MVST 3
- SWKH 0
- Target Price
- MVST $3.33
- SWKH N/A
- AVG Volume (30 Days)
- MVST 17.9M
- SWKH 10.0K
- Earning Date
- MVST 11-12-2024
- SWKH 11-14-2024
- Dividend Yield
- MVST N/A
- SWKH N/A
- EPS Growth
- MVST N/A
- SWKH N/A
- EPS
- MVST N/A
- SWKH 0.84
- Revenue
- MVST $370,989,000.00
- SWKH $24,725,000.00
- Revenue This Year
- MVST $19.19
- SWKH N/A
- Revenue Next Year
- MVST $29.35
- SWKH $6.17
- P/E Ratio
- MVST N/A
- SWKH $19.12
- Revenue Growth
- MVST 39.03
- SWKH N/A
- 52 Week Low
- MVST $0.15
- SWKH $15.14
- 52 Week High
- MVST $2.86
- SWKH $18.49
- Technical
- Relative Strength Index (RSI)
- MVST 65.98
- SWKH 47.18
- Support Level
- MVST $1.95
- SWKH $15.77
- Resistance Level
- MVST $2.86
- SWKH $16.20
- Average True Range (ATR)
- MVST 0.40
- SWKH 0.37
- MACD
- MVST 0.06
- SWKH -0.03
- Stochastic Oscillator
- MVST 73.60
- SWKH 34.75
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.